Please assess the completion status of the following clinical trial:

Trial Title: Topical Bevacizumab for Preventing Recurrent Pterygium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are diagnosed with primary pterygium and plan for pterygium excision with bare sclera by single surgeon. (G.N.)~* Patients with pterygium who understand and can follow the study protocol.~* Patients of age more than 30 years~Exclusion Criteria:~* Patients who have corneal melt, corneal epitheliopathy, abnormal corneal epithelial wound healing.~* Patients who are pregnancy or lactation.~* Patients who have a history of allergy to bevacizumab.~* Patients who have a history of allergy to steroid eye drops

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- bevacizumab eye drop (Type: EXPERIMENTAL): None
- placebo normal saline eye drop (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).